AMR El Dorado

Summary

AMR El Dorado is a medical facility located in El Dorado, Kansas. This center is recognized for care of Healthy Subjects, Type 2 Diabetes, Flu, Meningococcal Vaccination, Hypertension and other specialties. AMR El Dorado is involved with conducting 6 clinical trials across 13 conditions. There are 0 research doctors associated with this hospital, such as .

Top PIs

Clinical Trials running at AMR El Dorado

Type 2 Diabetes

Cardiovascular Disease

Obesity

Hypertension

High Blood Pressure

Bubonic Plague

Naltrexone + Bupropion

for Obesity

This trial studies the effects of a medication combination (naltrexone and bupropion) on heart health. It targets patients to see if this treatment increases the risk of major heart problems. The study also includes advice on diet and exercise. Naltrexone and bupropion have been used in combination for weight loss, but they have been associated with various adverse effects, including neuropsychiatric disorders and cardiovascular risks.

Recruiting

2 awards

Phase 4

23 criteria

Vicadrostat + Empagliflozin

for Type 2 Diabetes and Hypertension

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.

Recruiting

1 award

Phase 3

4 criteria